JP7780439B2 - Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物 - Google Patents

Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物

Info

Publication number
JP7780439B2
JP7780439B2 JP2022546588A JP2022546588A JP7780439B2 JP 7780439 B2 JP7780439 B2 JP 7780439B2 JP 2022546588 A JP2022546588 A JP 2022546588A JP 2022546588 A JP2022546588 A JP 2022546588A JP 7780439 B2 JP7780439 B2 JP 7780439B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
compound
pharmaceutically acceptable
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022546588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550641A (ja
JP2022550641A5 (enExample
Inventor
ジョルダネット，ファブリツィオ
エステルガールド イェンセン，モルテン
ジョギーニ，ビシュワナス
ジョン スノウ，ロジャー
Original Assignee
ディー．イー．ショウ リサーチ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディー．イー．ショウ リサーチ，エルエルシー filed Critical ディー．イー．ショウ リサーチ，エルエルシー
Publication of JP2022550641A publication Critical patent/JP2022550641A/ja
Publication of JP2022550641A5 publication Critical patent/JP2022550641A5/ja
Application granted granted Critical
Publication of JP7780439B2 publication Critical patent/JP7780439B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
JP2022546588A 2019-10-07 2020-10-06 Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物 Active JP7780439B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962911642P 2019-10-07 2019-10-07
US62/911,642 2019-10-07
PCT/US2020/054348 WO2021071803A1 (en) 2019-10-07 2020-10-06 Aryl heterobicyclic compounds as kv1.3 potassium shaker channel blockers

Publications (3)

Publication Number Publication Date
JP2022550641A JP2022550641A (ja) 2022-12-02
JP2022550641A5 JP2022550641A5 (enExample) 2024-05-23
JP7780439B2 true JP7780439B2 (ja) 2025-12-04

Family

ID=75436850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546588A Active JP7780439B2 (ja) 2019-10-07 2020-10-06 Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物

Country Status (11)

Country Link
US (1) US20230040182A1 (enExample)
EP (1) EP4041408A4 (enExample)
JP (1) JP7780439B2 (enExample)
KR (1) KR20220079575A (enExample)
CN (1) CN114728177B (enExample)
AU (1) AU2020363354A1 (enExample)
BR (1) BR112022006250A2 (enExample)
CA (1) CA3156981C (enExample)
IL (1) IL291867A (enExample)
MX (1) MX2022004144A (enExample)
WO (1) WO2021071803A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116782894A (zh) 2020-10-06 2023-09-19 D.E.肖研究有限责任公司 作为Kv1.3钾Shaker通道阻断剂的内酰胺化合物
CN114437070A (zh) * 2022-01-19 2022-05-06 广西-东盟食品检验检测中心 一种他达拉非新型衍生物的制备方法
JP2026513122A (ja) * 2022-10-28 2026-04-23 上海深勢唯思科技有限責任公司 芳香族複素環式Ｋｖ１．３阻害剤、その製造方法及び用途
WO2025029769A1 (en) 2023-07-31 2025-02-06 Eli Lilly And Company Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same
WO2026021011A1 (zh) * 2024-07-26 2026-01-29 浙江海正药业股份有限公司 芳基三环类衍生物及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004511516A (ja) 2000-10-17 2004-04-15 ワイス 膀胱の機能を調節する方法
JP2006512378A (ja) 2002-12-23 2006-04-13 ブリストル−マイヤーズ　スクイブ　カンパニー ３−置換−４−アリールキノリン−２−オン誘導体のアトロプ異性体
JP2007506749A (ja) 2003-09-23 2007-03-22 メルク　エンド　カムパニー　インコーポレーテッド イソキノリンカリウムチャネル阻害剤
WO2011073273A1 (en) 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365615B1 (en) * 1999-07-21 2002-04-02 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
CN100530013C (zh) * 2005-03-04 2009-08-19 松下电器产业株式会社 电子设备控制装置及其控制方法
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
US8124636B2 (en) * 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
TW201026708A (en) * 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
US20120065210A1 (en) * 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
TWI698438B (zh) * 2015-03-13 2020-07-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004511516A (ja) 2000-10-17 2004-04-15 ワイス 膀胱の機能を調節する方法
JP2006512378A (ja) 2002-12-23 2006-04-13 ブリストル−マイヤーズ　スクイブ　カンパニー ３−置換−４−アリールキノリン−２−オン誘導体のアトロプ異性体
JP2007506749A (ja) 2003-09-23 2007-03-22 メルク　エンド　カムパニー　インコーポレーテッド イソキノリンカリウムチャネル阻害剤
WO2011073273A1 (en) 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators

Also Published As

Publication number Publication date
WO2021071803A1 (en) 2021-04-15
CN114728177B (zh) 2025-06-24
EP4041408A1 (en) 2022-08-17
US20230040182A1 (en) 2023-02-09
AU2020363354A1 (en) 2022-04-21
KR20220079575A (ko) 2022-06-13
BR112022006250A2 (pt) 2022-06-21
CN114728177A (zh) 2022-07-08
CA3156981A1 (en) 2021-04-15
MX2022004144A (es) 2022-06-14
JP2022550641A (ja) 2022-12-02
IL291867A (en) 2022-06-01
EP4041408A4 (en) 2023-10-18
CA3156981C (en) 2025-06-17

Similar Documents

Publication Publication Date Title
JP7697954B2 (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン芳香族化合物
JP7780440B2 (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物
CN114728177B (zh) 作为Kv1.3钾Shaker通道阻滞剂的芳基杂二环化合物
JP2025186255A (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物
JP7763271B2 (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断剤としてのスピロインドリノン化合物
JP7716494B2 (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断剤としてのアリール複素環化合物
JP2023544404A (ja) Ｋｖ１．３カリウムＳＨＡＫＥＲチャネル遮断剤としてのラクタム化合物
IL322605A (en) Hydroquinazoline derivatives for the treatment of a disease or disorder
JP7822940B2 (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン複素環式化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251121

R150 Certificate of patent or registration of utility model

Ref document number: 7780439

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150